바이오인

The EU-Japan FTA - A key opportunity for the competitiveness of Europe's Innovative Pharmaceutical Industry and enhanced cooperation with Japan

Introduction

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has followed closely the exploration of a comprehensive Free Trade Agreement (FTA) with Japan. Our industry shares the views of the European Commission, and of many EU industrial sectors, that this has the potential to be a beneficial and strategically key agreement under the European Union's External Trade Strategy.

A comprehensive FTA negotiation with Japan represents a unique opportunity for the EU to address long-standing measures in Japan that are problematic for innovative pharmaceutical and biopharmaceutical products. In this context, Japan has committed to address a number of regulatory matters, including reforms in the short-term, as well as to work concretely on facilitating market access for pharmaceuticals for the benefit of patients. Just as significantly, FTA negotiations with Japan would provide a key framework for the EU to tangibly contribute to international efforts towards developing stronger transparency, regulatory and IPR rules and principles in the pharmaceutical sector, as well as other sectors. The significance of achieving successful and meaningful outcomes in these negotiations cannot be overstated, both to the benefit of key innovative European stakeholders and Europe’s knowledge-based economy overall.  

....(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.